Form 4: National Healthcare Corp Senior VP Granted Stock Options
SEC Form 4 Filing
Josh A. McCreary, Senior VP & General Counsel of National Healthcare Corp, reports the grant of stock options.
Summary
- Josh A. McCreary, Senior VP & General Counsel of National Healthcare Corp, filed a Form 4 on February 26, 2025, reporting a transaction.
- On February 24, 2025, McCreary was granted options to purchase 13,500 shares of National Healthcare Corp common stock at an exercise price of $90.62 per share.
- These options vest ratably over three years, starting February 24, 2026, and expire on February 24, 2030.
- McCreary directly owns 6,139 shares of National Healthcare Corp common stock.
- McCreary also holds options to purchase 3,734 shares at $63.96 expiring on 02/18/2027, 8,000 shares at $53.94 expiring on 03/08/2028 and 12,000 shares at $94.1 expiring on 03/05/2029.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. It reflects a standard executive compensation practice, aligning management interests with shareholders. There are no immediate negative implications.
Positives
- The grant of stock options aligns the executive's interests with those of the shareholders, incentivizing performance and value creation.
Future Outlook
The document does not contain specific forward-looking statements beyond the vesting schedule of the options.
Industry Context
Stock option grants are a common form of executive compensation in the healthcare industry, aligning management's interests with shareholder value.
Comparison to Industry Standards
- Stock option grants are a typical component of executive compensation packages in the healthcare sector.
- Companies like Brookdale Senior Living and Life Care Centers of America also utilize stock options as part of their compensation strategy.
- The vesting schedule and exercise price are generally determined based on industry benchmarks and company performance.
Stakeholder Impact
- The stock option grant could potentially increase shareholder value if the executive's performance leads to higher stock prices.
- The grant incentivizes the executive to make decisions that benefit the company and its stakeholders.
Key Dates
| Date | Description |
|---|---|
| 02/18/2023 | Date exercisable for options to purchase 3,734 shares at $63.96 |
| 02/18/2027 | Expiration date for options to purchase 3,734 shares at $63.96 |
| 03/08/2024 | Date exercisable for options to purchase 8,000 shares at $53.94 |
| 03/08/2028 | Expiration date for options to purchase 8,000 shares at $53.94 |
| 03/05/2025 | Date exercisable for options to purchase 12,000 shares at $94.1 |
| 02/24/2025 | Date of the option grant for 13,500 shares at $90.62 |
| 02/24/2026 | First vesting date for the newly granted options (1/3 of 13,500 shares) |
| 02/24/2027 | Second vesting date for the newly granted options (1/3 of 13,500 shares) |
| 03/05/2029 | Expiration date for options to purchase 12,000 shares at $94.1 |
| 02/24/2028 | Final vesting date for the newly granted options (1/3 of 13,500 shares) |
| 02/24/2030 | Expiration date for the newly granted options |
| 02/26/2025 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.